ArticleCureus2025
Cyto-Histomorphological Analysis of Thyroid Lesions and Risk Assessment of Malignancy/Neoplasia: Insights From a North Indian Tertiary Oncology Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Thyroid nodules, whether benign or malignant, are commonly identified as palpable or incidental findings. Accurate diagnosis is critical, with fine-needle aspiration cytology (FNAC) playing a crucial role in distinguishing between benign and malignant lesions. The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) standardizes FNAC reporting and estimates the risk of malignancy (ROM), aiding treatment decisions. This study aims to determine the risk of malignancy for each category of the Bethesda System and to evaluate the sensitivity and specificity of FNAC in diagnosing thyroid swellings. Methodology Clinicopathological data of thyroid FNAC and corresponding thyroid resection cases, collected over four years at the Department of Oncopathology, Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha National Institute, Varanasi, were analyzed. Results A total of 559 patients (372 females, 187 males) with a median age of 49 years were evaluated. Among the BSRTC categories, Category VI (32.4%) and Category II (29.2%) were the most common. ROM for each category was as follows: 50%, 25%, 30%, 85.71%, 97%, and 100%, respectively. FNAC demonstrated a sensitivity of 98%, a specificity of 64%, a positive predictive value of 96%, and a negative predictive value of 75%. Concordance between cytopathological and histopathological findings for malignant cases was 69.8%. Papillary thyroid carcinoma was the most common malignancy. Conclusions The ROM for categories I, II, and III was significant, highlighting the importance of the six-tier reporting system. The BSRTC system standardizes reporting and clinical management. Our data, primarily from an oncology center, may vary based on the expertise of the pathologist, laboratory setup, and patient demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.